Lupin traded at 2,128.60 this Monday February 2nd, decreasing 22.45 or 1.04 percent since the previous trading session. Looking back, over the last four weeks, Lupin lost 2.43 percent. Over the last 12 months, its price rose by 4.72 percent. Looking ahead, we forecast Lupin to be priced at 2,110.61 by the end of this quarter and at 1,993.80 in one year, according to Trading Economics global macro models projections and analysts expectations.
Lupin Limited is a pharmaceutical company. The Company is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) across the world. The Company offers products in the cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastro-intestinal, anti-infectives and non-steroidal anti-inflammatory drug therapy areas. The Company also offers solutions in the anti-tuberculosis (anti-TB) and cephalosporins therapy areas. The Company along with its subsidiaries has manufacturing locations spread across India, Japan, the United States, Mexico and Brazil. It has a pipeline of biosimilars addressing therapies, such as oncology, anti-inflammatory, anti-viral, rheumatoid arthritis, endocrinology, diabetes, ophthalmology and women's health. The Company's products include Antara, Methergine, Methylphenidate, Glumetza, Gluconorm, Tonact, Rcinex and Ramistar, among others.